Search
MiMedx Group Inc
MDXGAdd to Watchlist
4.130USD
-0.140-3.28%
Close 07-31 16:00（ET）Quotes delayed by 15 min
601.99MMarket Cap
19.87P/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-31The current earnings forecast score of MiMedx Group Inc is 8.00, ranking 171 out of 385 in the Biotechnology & Medical Research industry. The average price target is 12.00, with a high of 13.00 and a low of 12.00.
Analyst Rating
Based on
5
analysts
Buy
Current Rating
6.600
Target Price
+59.81%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
MiMedx Group Inc
MDXG
5
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
Kymera Therapeutics Inc
KYMR
24
Insmed Inc
INSM
23
1
2
3
...
99
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is MiMedx Group Inc's expected revenue for the next quarter?
MiMedx Group Inc's expected revenue is 70.53M.
What is MiMedx Group Inc's price target?
Analysts forecast that MiMedx Group Inc's price target is USD 12.00, with the highest forecast at USD 13.00 and the lowest forecast at USD 12.00.
How have MiMedx Group IncMDXG's recent earnings per share performed?
The market expectation was USD -0.10, while MiMedx Group IncMDXG's earnings per share (EPS) for the previous quarter was USD -0.07. EPS for the next quarter is expected at USD -0.02.
What is the analyst rating for MiMedx Group Inc?
Based on the ratings of MiMedx Group Inc's stock from 5 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.